NEW YORK (GenomeWeb News) - Bio-Rad said today that it has closed its acquisition of DiaMed Holding, a developer of blood-typing reagents and screening tools, in a transaction worth approximately 477 million Swiss francs ($405.8 million).
 
Bio-Rad announced its plans to acquire DiaMed in May.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.